HK1058946A1 - Hybrid human/porcine factor VIII - Google Patents

Hybrid human/porcine factor VIII

Info

Publication number
HK1058946A1
HK1058946A1 HK04101701A HK04101701A HK1058946A1 HK 1058946 A1 HK1058946 A1 HK 1058946A1 HK 04101701 A HK04101701 A HK 04101701A HK 04101701 A HK04101701 A HK 04101701A HK 1058946 A1 HK1058946 A1 HK 1058946A1
Authority
HK
Hong Kong
Prior art keywords
factor viii
porcine factor
hybrid human
domain
disclosed
Prior art date
Application number
HK04101701A
Other languages
English (en)
Inventor
John S Lollar
Marschall S Runge
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25342308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1058946(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory filed Critical Univ Emory
Publication of HK1058946A1 publication Critical patent/HK1058946A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
HK04101701A 1992-04-07 2004-03-08 Hybrid human/porcine factor VIII HK1058946A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/864,004 US5364771A (en) 1992-04-07 1992-04-07 Hybrid human/porcine factor VIII

Publications (1)

Publication Number Publication Date
HK1058946A1 true HK1058946A1 (en) 2004-06-11

Family

ID=25342308

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04101701A HK1058946A1 (en) 1992-04-07 2004-03-08 Hybrid human/porcine factor VIII

Country Status (12)

Country Link
US (2) US5364771A (es)
EP (2) EP1359222B1 (es)
JP (2) JP3440097B2 (es)
AT (2) ATE322544T1 (es)
AU (1) AU682147B2 (es)
CA (1) CA2133203C (es)
DE (2) DE69333724T2 (es)
DK (2) DK1359222T3 (es)
ES (2) ES2235154T3 (es)
HK (1) HK1058946A1 (es)
PT (1) PT1359222E (es)
WO (1) WO1993020093A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2343916A1 (en) 1998-09-21 2000-03-30 Genetics Institute, Inc. Methods of downmodulating the immune response to therapeutic proteins
DK1129186T4 (da) † 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
CA2434097A1 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
AU2002327430A1 (en) * 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
EP1572889B1 (en) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
CA2462966A1 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
EP1682106A4 (en) * 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII FACTOR WITH REDUCED IMMUNOGENICITY THROUGH MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
JP2008537680A (ja) * 2005-04-14 2008-09-25 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
ATE474917T1 (de) * 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
CA2728012C (en) 2008-06-24 2017-10-31 Csl Behring Gmbh Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
PL2499165T3 (pl) 2009-11-13 2017-04-28 Grifols Therapeutics Inc. Preparaty zawierające czynnik von willenbranda (vwf) oraz sposoby, zestawy i zastosowania z nim powiązane
AU2010325787B2 (en) 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
EP2555793B1 (en) * 2010-04-08 2015-07-08 Baxter International Inc. Methods for modeling protein stability
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
CA2816575C (en) 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
SI2802668T1 (sl) 2012-01-12 2019-01-31 Bioverativ Therapeutics Inc. Zmanjšanje imunogeničnosti proti faktorju VIII pri posameznikih, ki se zdravijo zaradi faktorja VIII
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
KR102403545B1 (ko) 2012-07-11 2022-05-30 바이오버라티브 테라퓨틱스 인크. Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3904376A1 (en) 2013-06-24 2021-11-03 Xiao, Weidong Mutant factor viii compositions and methods
SG10201913738YA (en) 2013-06-28 2020-03-30 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
CA1341174C (en) * 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins

Also Published As

Publication number Publication date
DE69334003T2 (de) 2007-01-25
EP0638088A1 (en) 1995-02-15
JPH07508404A (ja) 1995-09-21
CA2133203C (en) 2002-07-02
JP2003174876A (ja) 2003-06-24
DE69333724D1 (de) 2005-01-20
CA2133203A1 (en) 1993-10-14
JP3440097B2 (ja) 2003-08-25
PT1359222E (pt) 2006-07-31
AU682147B2 (en) 1997-09-25
ES2261866T3 (es) 2006-11-16
ATE322544T1 (de) 2006-04-15
DK1359222T3 (da) 2006-06-19
EP1359222A3 (en) 2003-11-19
ES2235154T3 (es) 2005-07-01
DK0638088T3 (da) 2005-04-25
ATE284963T1 (de) 2005-01-15
DE69334003D1 (de) 2006-05-18
EP1359222A2 (en) 2003-11-05
DE69333724T2 (de) 2005-11-10
EP0638088A4 (en) 1996-06-26
EP1359222B1 (en) 2006-04-05
EP0638088B1 (en) 2004-12-15
WO1993020093A1 (en) 1993-10-14
US5583209A (en) 1996-12-10
AU4279993A (en) 1993-11-08
US5364771A (en) 1994-11-15
JP3495365B2 (ja) 2004-02-09

Similar Documents

Publication Publication Date Title
HK1058946A1 (en) Hybrid human/porcine factor VIII
DE69404840D1 (de) Hybridzentralelektrik
EP0573240A3 (en) Reference voltage generator.
KR100334423B1 (ko) 전기자동차
EP0661616A3 (en) Bandgap type reference voltage generator.
EP0619123A3 (en) Regenerative electrical stimulator.
AU1398792A (en) Hybrid polypeptide
DE69412582D1 (de) Hochspannungsgleichstromübertragung
EP0447833A3 (en) Low noise dac current source topology
DE69315214D1 (de) Elektrische zahnbürste
GB2282708B (en) Electrical motor-generator
GB2267041B (en) Toy block for use with power source
AU2640592A (en) Electric car
EP0611105A3 (en) Power source.
EP0629049A3 (en) Digital-to-analog converter with low supply voltage.
EP0481277A3 (en) Current source
GB2273201B (en) High reliablity contact scheme
PH25883A (en) Current source technology
SU1617417A1 (ru) Иctoчhиk пиtahия пoctoяhhoгo haпpяжehия
RU1821879C (en) D c voltage source
KR940020501U (ko) 자동차용 전기포트
AU14P (en) FIREFLY Anigozanthos hybrid
ITRM920934A0 (it) Veicolo individuale azionato meccanicamente con l'ausilio di un motoreelettrico.
SG90594G (en) Current source technology.
CS8904228A1 (en) Pulse-controlled current source

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110407